Mustang Bio (NASDAQ:MBIO) Stock Price Up 3.8% – Still a Buy?

Mustang Bio, Inc. (NASDAQ:MBIO)’s share price rose 3.8% during mid-day trading on Monday . The stock traded as high as $0.6540 and last traded at $0.6520. 13,912 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 38,956 shares. The stock had previously closed at $0.6282.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mustang Bio in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Mustang Bio currently has a consensus rating of “Sell”.

Mustang Bio Stock Up 3.8%

The stock has a market capitalization of $4.94 million, a price-to-earnings ratio of -1.36 and a beta of 2.05. The company’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.81.

Mustang Bio (NASDAQ:MBIO) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($140.00) by $139.86.

Institutional Trading of Mustang Bio

An institutional investor recently bought a new stake in Mustang Bio stock. DRW Securities LLC purchased a new stake in Mustang Bio, Inc. (NASDAQ:MBIO) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned approximately 1.01% of Mustang Bio as of its most recent SEC filing. Hedge funds and other institutional investors own 9.95% of the company’s stock.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.